These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29642099)

  • 21. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
    Granger MM; Naranjo A; Bagatell R; DuBois SG; McCune JS; Tenney SC; Weiss BD; Mosse YP; Asgharzadeh S; Grupp SA; Hogarty MD; Gastier-Foster JM; Mills D; Shulkin BL; Parisi MT; London WB; Han-Chang J; Panoff J; von Allmen D; Jarzembowski JA; Park JR; Yanik GA
    Transplant Cell Ther; 2021 Jun; 27(6):490.e1-490.e8. PubMed ID: 33823167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
    Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
    Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials.
    Choderlos de Laclos X; Risbourg S; Brennan B; Bertucci F; Gaspar N; Gelderblom H; Hawkins DS; Janeway K; Juergens H; Kasper B; Krailo MD; Cécile Le Deley M; Marec-Bérard P; McCabe MG; Metzler M; Ranft A; Strauss S; Tabone MD; Windsor R; Dirksen U; Gandemer V
    Eur J Cancer; 2024 Sep; 208():114229. PubMed ID: 39032218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.
    Valteau-Couanet D; Benhamou E; Vassal G; Stambouli F; Lapierre V; Couanet D; Lumbroso J; Hartmann O
    Bone Marrow Transplant; 2000 May; 25(9):937-42. PubMed ID: 10800060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
    Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
    Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
    Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
    Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response-adapted consolidation therapy strategy for patients with metastatic high-risk neuroblastoma: Results of the SMC NB-2014 study.
    Seo ES; Lee JW; Cho HW; Ju HY; Cho YS; Lee S; Moon SH; Yoo KH; Lim DH; Sung KW
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31173. PubMed ID: 38965702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation.
    Hartmann O; Valteau-Couanet D; Benhamou E; Vassal G; Rubie H; Beaujean F; Lemerle J
    Eur J Cancer; 1997 Oct; 33(12):2126-9. PubMed ID: 9516867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.
    Miano M; Garaventa A; Pizzitola MR; Piccolo MS; Dallorso S; Villavecchia GP; Bertolazzi C; Cabria M; De Bernardi B
    Bone Marrow Transplant; 2001 Mar; 27(6):571-4. PubMed ID: 11319584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
    Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
    Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
    De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
    Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
    J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.
    Proust-Houdemont S; Pasqualini C; Blanchard P; Dufour C; Benhamou E; Goma G; Semeraro M; Raquin MA; Hartmann O; Valteau-Couanet D
    Bone Marrow Transplant; 2016 Aug; 51(8):1076-81. PubMed ID: 27042850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
    Pession A; Prete A; Locatelli F; Bella S; Melchionda F; Garaventa A; Burnelli R; Paolucci G
    Med Pediatr Oncol; 1999 Nov; 33(5):450-4. PubMed ID: 10531568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma.
    Corbett R; Pinkerton R; Tait D; Meller S
    J Nucl Biol Med (1991); 1991; 35(4):228-31. PubMed ID: 1823824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
    Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
    Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
    DuBois SG; Groshen S; Park JR; Haas-Kogan DA; Yang X; Geier E; Chen E; Giacomini K; Weiss B; Cohn SL; Granger MM; Yanik GA; Hawkins R; Courtier J; Jackson H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Villablanca JG; Marachelian A; Matthay KK
    Clin Cancer Res; 2015 Jun; 21(12):2715-21. PubMed ID: 25695691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.